Journal ArticleDOI
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
Raluca Pais,Frédéric Charlotte,Larissa Fedchuk,Pierre Bedossa,Pascal Lebray,Thierry Poynard,Vlad Ratziu +6 more
TLDR
A substantial proportion of patients with NAFL can progress towards well-defined NASH with bridging fibrosis, especially if metabolic risk factors deteriorate, and current monitoring practices of these patients should be revised.About:
This article is published in Journal of Hepatology.The article was published on 2013-09-01. It has received 417 citations till now. The article focuses on the topics: Fatty liver & Steatohepatitis.read more
Citations
More filters
Journal ArticleDOI
High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression
TL;DR: Personalized approaches to NAFLD/NASH management should take these “high-risk” categories of NAFLDs progression into account in order to reduce NAFLd/Nash-associated morbidity and mortality.
Book ChapterDOI
Obesity and Nonalcoholic Fatty Liver Disease
TL;DR: The diagnosis of NAFLD is challenging because of the lack of a robust noninvasive test, and several assessment tools comprising of biochemical and radiologic features are available but are not sensitive or specific for accurate assessment.
Book ChapterDOI
Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease
TL;DR: This chapter exposes the different diagnostic and follow-up tools available for non-alcoholic fatty liver disease, and with them an algorithm according to the recommendations and the current evidence is made.
References
More filters
Journal ArticleDOI
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
David E. Kleiner,Elizabeth M. Brunt,Mark L. Van Natta,Cynthia Behling,Melissa J. Contos,Oscar W. Cummings,Linda D. Ferrell,Yao Chang Liu,Michael Torbenson,Aynur Unalp-Arida,Matthew M. Yeh,Arthur J. McCullough,Arun J. Sanyal +12 more
TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.
Journal ArticleDOI
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Anna Mae Diehl,Elizabeth M. Brunt,Kenneth Cusi,Michael Charlton,Arun J. Sanyal +7 more
TL;DR: This is a practice guideline for clinicians rather than a review article and interested readers can refer to several comprehensive reviews published recently.
Journal ArticleDOI
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
Christi A. Matteoni,Zobair M. Younossi,Terry Gramlich,Navdeep Boparai,Yao Chang Liu,Arthur J. McCullough +5 more
TL;DR: The outcome of cirrhosis and liver-related death is not uniform across the spectrum of nonalcoholic fatty liver, and poor outcomes are more frequent in patients in whom biopsies show ballooning degeneration and Mallory hyaline or fibrosis.
Journal ArticleDOI
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Leon A. Adams,James F. Lymp,Jenny St. Sauver,Schuyler O. Sanderson,Keith D. Lindor,Ariel E. Feldstein,Paul Angulo +6 more
TL;DR: Mortality among community-diagnosed NAFLD patients is higher than the general population and is associated with older age, impaired fasting glucose, and cirrhosis, although the absolute risk is low.
Journal ArticleDOI
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
Giulio Marchesini,Elisabetta Bugianesi,Gabriele Forlani,Fernanda Cerrelli,Marco Lenzi,R. Manini,S. Natale,Ester Vanni,Nicola Villanova,Nazario Melchionda,Mario Rizzetto +10 more
TL;DR: The presence of multiple metabolic disorders is associated with a potentially progressive, severe liver disease and the increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades.